| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| 영문 | liver function tests | 한글 | 간기능검사 |
|---|---|---|---|
| 설명 | 혈액검사중 가장 많이 쓰이는 검사법으로 다음 7가지를 검사하게 된다. 혈청콜레스테롤, 총단백질, 알부민, 빌리루빈, GOT/GPT 효소, 알칼리인산분해효소(alkaline phophatase) 등을 검사하게 되는 데 각 검사치에는 모두 의미가 있으며, 이 검사 하나로 간기능의 전반적인 상태에 대해서 알아볼 수 있다. |
||
| 영문 | pulmonary function tests | 한글 | 폐기능 검사 |
|---|---|---|---|
| 설명 | 여러 가지 기구를 이용해 폐용적 및 허파의 확산능을 알아보는 검사로 말 그대로 허파의 기능을 측정하는 검사이다. |
||
| 영문 | obsessive-compulsive disorder | 한글 | 강박반응성 장애 |
|---|---|---|---|
| 설명 | 강박사고(obsession)은 반복되는 사고를 말하며, 강박행위(compulsion)는 반복되는 행동을 말한다. 즉 반복되는 사고에 따라 반복적인 행동을 수행하는 장애를 말한다. 이때 반복적인 사고는 이론적으로 이해되지 않는 경우가 많고, 본인도 이런 사고가 이해되지 않는다는 사실을 알고 고치려고 하지만, 잘 되지 않는다. 또한 계속적으로 이런 사고에 따른 반복적인 행동을 하며, 이런 행동을 수행치 않을 시, 본인의 의지와 무관하게 몹시 불안해하고, 초조해한다. |
||
| 영문 | panic disorder | 한글 | 공황장애 |
|---|---|---|---|
| 설명 | 반복되는 공황발작(panic attack: 갑작스런 공포상태의 발병)과 신경과민을 나타내는 경우를 말함. 공황발작은 단독으로 일어나기보다는 오랜 긴장상태에서 주기적으로 일어나는 현상으로 보인다. 공황발작의 증상은 급격한 자율신경자극증상으로 호흡곤란, 심장박동항진, 흉부통증, 흉부압박감, 질식감, 현기증, 불안정한 느낌 등이다. 대개 갑자기 일어나 수분동안 지속했다가 소실되는 것이 보통이다. 드물게는 수시간 지속되기도 한다. 공황발작은 주기적으로 반복되면서 만성화하는 경향이 많다. 신경과민은 공황발작이 없는 시기의 증상이다. 감당키 어려운 공황발작에 대한 예기불안(그 일이 일어나지 않을까 하는 느낌 때문에 오는 불안)이 있고 그 때문에 조심스러워지고 주위를 살피는 태도도 나타나서 신경은 극도로 날카로워진다. 공포장애에서도 이런 공황발작이 올 수 있으나, 이 경우는 특별한 대상이나 상황이 있는 것에 반해 공황장애는 이런 특별한 사건없이 주기적으로 발생한다. 치료는 항불안제와 때로는 항우울제를 사용한다. |
||
| PULSES | physical condition, upper limb function, lower limb function, sensory component, excretory function,... |
|---|---|
| PFT | 1) Platelet Function Test 2) Pulmonary Function Test |
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| LFA | left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct... |
| AF-1 | Activation function 1 |
|---|---|
| CFAM | Cerebral Function Analysing Monitor |
| CFM | Cerebral Function Monitor |
| CSF | Contrast Sensitivity Function |
| DGF | Delayed graft function |
| platelet function disorders | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (31 Dec 1997) |
|---|
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
|---|---|
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| platelet actomyosin | The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function. Synonym: thrombosthenin. (05 Mar 2000) |
| platelet adhesiveness | The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces. (12 Dec 1998) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
| platelet basic protein | <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|